# MORPHEUS (NCT03051464)

> Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: stage II–III rectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03051464
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
- Conditions: Stage II Rectal Cancer; Organ Preservation; Non-operative Treatment; Rectal Cancer (Stage III); Rectal Cancer Patients
- Interventions: Complete responders and Non-complete responders; Chemoradiation + EBRT Boost; Chemoradiation + HDRBT Boost
- Enrollment: 131
- Primary outcome: TME-free survival

## Indexed commentary on MORPHEUS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 25
- YouTube: 17
- Podcasts: 16

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=morpheus-nct03051464

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03051464", "email": "<work email>"}; the inbox owner confirms by the emailed link.